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  The aim of the present study was to elucidate the direct effects of melatonin on bladder activity 
and to determine the mechanisms responsible for the detrusor activity of melatonin in the isolated 
rat bladder. We evaluated the effects of melatonin on the contractions induced by phenylephrine (PE), 
acetylcholine (ACh), bethanechol (BCh), KCl, and electrical field stimulation (EFS) in 20 detrusor 
smooth muscle samples from Sprague-Dawley rats. To determine the mechanisms underlying the 
inhibitory responses to melatonin, melatonin-pretreated muscle strips were exposed to a calcium 
channel antagonist (verapamil), three potassium channel blockers [tetraethyl ammonium (TEA), 
4-aminopyridine (4-AP), and glibenclamide], a direct voltage-dependent calcium channel opener (Bay 
K 8644), and a specific calcium/calmodulin-dependent kinase II (CaMKII) inhibitor (KN-93). Melatonin 
pretreatment (10
－8∼10
－6 M) decreased the contractile responses induced by PE (10
－9∼10
－4 M) and 
Ach (10
－9∼10
－4 M) in a dose-dependent manner. Melatonin (10
－7 M) also blocked contraction induced 
by high KCl ([KCl]ECF; 35 mM, 70 mM, 105 mM, and 140 mM) and EFS. Melatonin (10
－7 M) potentiated 
the relaxation response of the strips by verapamil, but other potassium channel blockers did not change 
melatonin activity. Melatonin pretreatment significantly decreased contractile responses induced by 
Bay K 8644 (10
－11∼10
－7 M). KN-93 enhanced melatonin-induced relaxation. The present results 
suggest that melatonin can inhibit bladder smooth muscle contraction through a voltage-dependent, 
calcium-antagonistic mechanism and through the inhibition of the calmodulin/CaMKII system.
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INTRODUCTION
  Nocturia is the complaint of having to wake at night to 
void [1], particularly in older adults [2]. Nocturia is often 
less responsive than other lower urinary tract symptoms 
after medical or surgical treatment for benign prostatic hy-
perplasia (BPH) [3]. Nocturia is a complex medical con-
dition that can result from several factors, including re-
duced bladder capacity, the excessive production of urine 
at night (nocturnal polyuria), or a combination of these two 
causes. It can also result from a primary sleep disorder [4].
  Melatonin (N-acetyl-5-methoxytryptamine) is a pineal 
gland hormone secreted predominantly at night. Nocturnal 
production of melatonin is impaired in older adults, and 
several clinical trials have demonstrated that exogenous 
administration of melatonin to this group improves sleep 
[5,6] and habitual nocturnal voiding [7,8]. Melatonin in-
creases bladder capacity and decreases urine volume via 
a central nervous system (CNS) effect [9] and also relaxes 
involuntary or increased bladder contractions via periph-
eral nervous system effects [10]. It is a prime physiological 
determinant of circadian rhythms and influences the phys-
iological decrease in urine output and frequency at night 
in healthy individuals, either directly or indirectly through 
effects on other hormones [1]. Melatonin exerts many of its 
physiological actions through interaction with the mem-
brane receptors MT1 and MT2 and intracellular proteins 
such as quinine reductase 2, calmodulin, calreticulin, and 
tubulin. Melatonin receptors are expressed in various parts 
of the CNS and in peripheral organs including kidney, blad-
der, and prostate [11].
  Melatonin was originally described as a potent anti-38 JH Han, et al
oxidant [12]. Melatonin has a modulatory effect on gastro-
intestinal smooth muscle motility, and both contractile and 
relaxant effects have been reported [10,13]. In the bladder, 
melatonin inhibits ACh- and KCl-induced contraction [10]. 
However, the exact mechanism responsible for the effects 
of melatonin on smooth muscle is unknown.
  Therefore, we performed the present study to elucidate 
the direct effect of melatonin on bladder activity and to de-
termine the mechanism underlying melatonin-based modu-
lation of detrusor activity in isolated rat bladder tissue.
METHODS
Preparation of rat bladder strips and measurement of 
tension
  A total of 20 Sprague-Dawley rats, weighing 150∼200 
g, were used in this study. All protocols were performed 
in accordance with the recommendations of the ethics 
Committee for the Protection of Persons and Animals at 
the Institute of Medical Science, Chung-Ang University, 
Seoul, Korea. The rats were asphyxiated by placement into 
a tight container with 100% CO2 gas for 30 sec and were 
then sacrificed by a cut to the carotid artery. The abdomen 
was opened and the urinary bladder was surgically re-
moved and transferred to a Petri dish containing HEPES 
buffered physiological salt solution (composition in mM: 
NaCl, 140; KCl, 4; CaCl2, 2; MgCl2, 1; NaHPO4, 1.2; L-glu-
cose, 11; HEPES, 5; pH adjusted to 7.4 with NaOH) with 
100% O2 saturation. The strips were then trimmed to 2×1×5 
mm and the urothelium was removed. The strips were pre-
pared from the lower half of the bladder.
  T h e  s t r i p s  w e r e  m o u n t e d  i n  a  2 0  m l  o r g a n  b a t h  f i l l e d  
with physiological salt solution (composition in mM: NaCl, 
114; NaHCO3, 26; KCl, 4; CaCl2, 2; MgCl2, 1; NaHPO4, 1.2; 
L-glucose, 11; HEPES, 5; pH adjusted to 7.4 with HCl). The 
solution in the bath was bubbled with mixed gas (95% O2, 
5% CO2) and maintained at 37
oC and exchanged at 30 min 
intervals. The strips were connected to an isometric force 
transducer (52-9545, Harvard Instruments, London, UK) 
and the measurements were recorded on a MacLab 4e digi-
tal recording system (AD Instruments, Bella Vista, NSW, 
Australia). Resting tension was adjusted to 0.2 g over 60 
min for the equilibration period.
Contractile responses of the strips
1. Contraction induced by acetylcholine (ACh), bethanechol 
(BCh), phenylephrine (PE), or KCl
  Strips were pretreated with melatonin (10
－8∼10
－6 M) for 
10 min, followed by successive logarithmic increments of 
PE, ACh, or BCh (all 10
－9∼10
－4). 
2. Contraction induced by KCl or electrical field stimulation 
(EFS)
  For KCl experiments, strips were pretreated with 10
－7 
M melatonin followed by KCl. KCl concentrations in the 
extracellular fluid ([KCl]ECF) for the four KCl-treated con-
ditions were 35 mM, 70 mM, 105 mM, and 140 mM. EFS 
was performed using two platinum plate electrodes (5×10 
mm) set parallel to each other beside the strips. Electrical 
impulses were delivered with a stimulator (6012, Harvard 
Instruments, London, UK). The strips were stimulated with 
rectangular pulses of 0.2 msec and 50 V, at a stimulation 
frequency of 1∼40 Hz. Trains of pulses lasted for 3 sec, 
and there was an interval of 2 min between stimulations.
3. Mechanisms responsible for the relaxation responses to 
melatonin
  The basal tension of each strip was adjusted to the opti-
mal isometric tension, at which contraction elicited by PE 
10
－5 M was maximal. After pretreatment with 10
－7 M mel-
atonin, relaxation was measured in response to successive 
logarithmic increments of a calcium channel blocker 
(verapamil; 10
－9∼10
－4 M). Melatonin-induced inhibition of 
dose-dependent PE (10
－9∼10
－4)-induced contraction re-
sponses was measured in the presence of three potassium 
channel blockers [tetraethyl ammonium (TEA; 1 mM and 
10 mM), 4-aminopyridine (4-AP; 10
－5 M), and 10
－5 M gli-
benclamide]. After pretreatment with 10
－7 M melatonin, 
Bay K 8644 (a calcium channel opener; 10
－11∼10
－7 M)-in-
duced contractions were assessed. After bladder strips were 
incubated for 10 min in the absence or the presence of mela-
tonin (10
－7 M) alone or in combination with KN-93 [a spe-
cific calcium/calmodulin-dependent kinase II (CaMKII) in-
hibitor: 10
－6 M], differences in KCl (35 mM)-induced con-
traction were evaluated.
Solutions and reagents
  All chemicals were obtained from Sigma Chemical Com-
pany (St. Louis, MO, USA).
Statistical analysis
  The SPSS software package version 14.0 (Statistical 
Package for Social Sciences
TM, Chicago, IL, USA) was used 
for the statistical analysis. Data are representative of more 
than five replicates. Statistical analysis was performed by 
Student’s t-test and ANOVA, with significance at p＜0.05.
RESULTS
Melatonin pretreatment blocks contraction induced by 
PE, ACh and BCh in a dose-dependent manner
  Melatonin alone (10
－8∼10
－6 M) did not change strip rela-
xation (data not shown). However, pretreatment with 10
－8
∼10
－6 M melatonin decreased the contractile responses in-
duced by PE (10
9∼10
－4 M) in a dose-dependent manner 
(n=8, Fig. 1A). Melatonin also attenuated ACh- and BCh-in-
duced (10
－9∼10
－4 M) contractions, which were stronger 
than PE contractions; however, the inhibitory effects of 
melatonin on contractions were not reversed by luzindole 
(a melatonin-receptor antagonist) (n=12, Fig. 1B; n=12, Fig. 
2A). 
Melatonin inhibits contractions induced by KCl and 
EFS
  Melatonin pretreatment (10
－7 M) decreased induced con-
tractions at four KCl concentrations ([KCl]ECF; 35 mM, 70 
mM, 105 mM, and 140 mM) (n=8, Fig. 2B). Melatonin (10
－7 
M) also inhibited contractions induced by EFS (1∼ 40 Hz) 
(n=8, Fig. 3A). Effects of Melatonin on Bladder Contraction 39
       
Fig. 1. Effects of melatonin pretreatment (10
－8∼10
－6 M) on the concentration-response curve for phenylephrine (10
9∼10
－4 M) and 
acetylcholine (10
－9∼10
－4 M) in Sprague-Dawley rat detrusor smooth muscles. (A) Pretreatment with melatonin dose-dependently decreased
the contractile responses induced by phenylnephrine (n=8 in each). (B) Melatonin blocked acetylcholine-induced contractions, which were 
stronger than phenylnephrine contractions (n=12 in each). Asterisk means p＜0.05. Each point represents the mean±standard error of 
m e a n s  ( S E M ) ;  i f  t h e  S E M s  w e r e  n o t  s h o w n ,  t h e bars fall within the size of the symbols.
       
Fig. 2. Effects of melatonin pretreatment (10
－8∼10
－6 M) on the concentration-response curve for bethanechol (10
－9∼10
－4 M) and effects 
of 10
－7 M melatonin pretreatment on the KCl-induced contractions ([KCl]ECF ; 35 mM, 70 mM, 105 mM and 140 mM) in Sprague-Dawley 
rat detrusor smooth muscles. (A) Melatonin blocked bethanechol-induced contractions, which were stronger than phenylnephrine contractions,
but contraction inhibition effects of the melatonin were not reversed by luzindazole (a melatonin receptor antagonist) (n=12 in each). (B) 
The melatonin inhibited the contractions at all four conditions of high extracellular KCl concentrations (n=8 in each). Asterisk means 
p＜0.05. Each point represents the mean±standard error of means (SEM).
Mechanisms of melatonin inhibition through calcium 
channel blocking effects
  Melatonin (10
－7 M) potentiated the relaxation induced 
by treatment with the calcium channel antagonist (verapa-
mil; 10
－9∼10
－4 M) (n=8, Fig. 3B). However, none of the 
potassium channel blockers [TEA (1 mM and 10 mM), 4-AP 
(10
－5 M), and glibenclamide (10
－5 M)] changed melatonin 
activity (data not shown). The contractile responses induced 
by the direct calcium channel opener (Bay K 8644; 10
－11∼
10
－7 M) were significantly decreased by 10
－7 M melatonin 
pretreatment (n=6, Fig. 4A). KN-93 at 10
－6 M concentration 
enhanced melatonin-induced inhibition of KCl-induced con-
tractions (n=12, Fig. 4B).
DISCUSSION
  Detrusor overactivity is frequently associated with over-
active bladder (OAB) symptoms and is urodynamically 
characterized by involuntary detrusor contractions during 
bladder filling [1]. Large-scale, randomized and controlled 
studies have shown that patients receiving any type of oral 
antimuscarinic agent report a significant improvement in 
OAB symptoms [14]. However, despite these initial positive 
responses, antimuscarinics may fall short because of sub-
stantial side effects, insufficient effects on continuing incon-
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Fig. 3. Effects of 10
－7 M melatonin pretreatment on the frequency-response curve for electrical field stimulation (EFS, 1∼40 Hz) and 
effects of 10
－7 M melatonin pretreatment on the concentration-response curve for verapamil relaxation (10
－9∼10
－4 M) in Sprague-Dawley
rat detrussor muscles. (A) The melatonin significantly inhibited the EFS-induced contractions (n=8 in each). (B) The basal tension of each
strip was adjusted to the optimal isometric tension at which contraction with phenylephrine 10-5 M was maximal. The curve was slightly 
but significantly inhibited by melatonin pretreatment (n=8 in each). Asterisk means p＜0.05. Each point represents the mean±standard
error of means (SEM) of the results.
      
Fig. 4. Effects of 10
－7 M melatonin pretreatment on the concentration-response curve for Bay K 8644 contraction (10
－11∼10
－7 M) in 
Sprague-Dawley rat detrussor muscles and in the absence or the presence of melatonin (10
－7 M) alone or combination with KN-93 (a 
specific calcium/calmodulin-dependent kinase II inhibitor: 10
－6 M), the differences of KCl (35 mM)-induced contraction were evaluated. 
(A) The contractile responses of Bay K 8644 were almost completely inhibited by melatonin (n=6 in each). (B) KN-93 at 10
－6 M concentration
enhanced the melatonin-induced inhibiting effects of the KCl-induced contraction (n=12 in each). Asterisk means p＜0.05. Each point 
represents the mean±standard error of means (SEM) of the results.
tinence, and long term compliance problems [15].
  Melatonin is short-lived, with a half-life of only 40 to 50 
minutes. Melatonin is safe in older adults, with few adverse 
effects. Documented side effects include decreased body 
temperature, sedation, headache, depression, tachycardia, 
and pruritus [16]. Melatonin, either alone or in combination 
with other agents, may help some patients in whom current 
options are ineffective or contraindicated. Onur et al. [17] 
reported that the combined use of low dose trospium and 
melatonin exerted strong in vitro inhibition of agonist-in-
duced contractions in rat bladder strips.
  Nocturnal production of melatonin is impaired in older 
adults. Drake et al. [7] showed that the administration of 
melatonin (2 mg/day) for four weeks improved nocturia 
safely in patients with bladder outlet obstruction, and 
Sugaya et al. [8] reported that the night-time serum mela-
tonin level was significantly lower in elderly persons than 
in younger persons. Furthermore, the night serum melato-
nin level in elderly persons with nocturia was lower than 
that in elderly persons without nocturia. Several clinical 
trials have demonstrated that exogenous administration of 
melatonin to this group can improve sleep disorders [5,6]. 
The use of a controlled-release melatonin formulation en-
ables the maintenance of melatonin concentrations that are 
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sufficiently effective to improve sleep in older adults 
throughout the night, with a single low dose [5]. Even in 
those patients with obvious medical reasons for nocturia, 
sleep disorders are the source of almost all awakenings 
from sleep and can contribute to habitual rising at night 
to urinate [18]. 
  Melatonin, an endogenous hormone, inhibits bladder con-
tractions induced by PE, ACh, and EFS in a dose-dependent 
manner. Semerciöz et al. [10] similarly reported that mela-
tonin inhibits ACh-induced contractions in isolated bladder 
strips from guinea pigs. However, neither the effect of mela-
tonin on adrenoceptor agonist-induced contraction nor the 
mechanism of action underlying this effect has been pre-
viously studied. Adrenoceptors play a prominent role in the 
pathogenesis of lower urinary tract symptoms and related 
irritative bladder symptoms [19]. In the present study, mel-
atonin alone did not induce the relaxation response in the 
bladder strips, but melatonin did inhibit Ach-, BCh-, PE-, 
and EFS-induced contraction. Melatonin therefore has po-
tential as a candidate bladder-calming modulator.
    Melatonin exerts many of its physiological actions 
through interaction with the membrane receptors MT1 and 
MT2 and intracellular proteins such as quinine reductase 
2, calmodulin, calreticulin, and tubulin. Melatonin re-
ceptors are expressed not only in the bladder but also in 
the prostate [11]. Melatonin has dual effects on the vascula-
ture, with vasoconstriction through MT1 and vasodilation 
through MT2 [20]. However, in the present study, the con-
traction inhibitory effects of melatonin were not reversed 
by luzindole (a melatonin receptor antagonist). These re-
sults offer the possibility that melatonin-induced inhibition 
of bladder contraction may be mediated by the direct modu-
lation of intracellular proteins because melatonin has the 
permeability of cell membrane.
  Melatonin may also influence bladder contractility via 
calmodulin [21]. Melatonin can bind to Ca
2＋-activated 
calmodulin with high affinity and prevent it from activating 
myosin light-chain kinase, leading to decreased contractil-
ity [21]. Similarly, melatonin may directly affect the ion 
channels responsible for regulating bladder contraction or 
changing membrane potentials that affect other ion chan-
nels [12]. KN-93 selectively inhibits CaMKII activity by 
binding directly and selectively to the calmodulin binding 
site of CaMKII and preventing the association of calm-
odulin and CaMKII [22]. Our study found that KN-93 en-
hanced the melatonin-induced relaxation response in the 
bladder strips, indicating that melatonin may act on the 
calmodulin/CaMKII system.
  Experiments involving myometrial contractions showed 
that melatonin can inhibit spontaneous and oxytocin-in-
duced contractions in pregnant and non-pregnant rats [12]. 
Melatonin inhibits KCl-induced contractions in isolated 
bladder strips from guinea pigs [10]. In the present study, 
melatonin inhibited KCl-induced contraction. Melatonin po-
tentiated the relaxation response of the bladder induced by 
verapamil, but potassium channel blockers did not change 
melatonin activity. In general, high K
＋-induced contraction 
is known to be evoked by Ca influx through the opening 
of voltage-dependent Ca channel. So the contraction is in-
dependent pathway from the K channel activity. Moreover, 
melatonin decreased the contractile responses induced by 
Bay K 8644 (10
－11∼10
－7 M), indicating the potential an-
tagonism of voltage-dependent Ca
2＋ channels. Melatonin 
may therefore act as a calcium antagonist on rat detrusor 
muscles.
  In conclusion, the decrease in bladder contraction in-
duced by melatonin may be mediated by the inhibition of 
the calmodulin/CaMKII system and voltage-dependent cal-
cium channels in the rat bladder. Whether these two mech-
anisms act independently or in a complementary manner 
requires further study.
ACKNOWLEDGEMENTS
  This study was supported by a grant from the Korea 
Healthcare Technology R&D Project, Ministry for Health, 
Welfare, and Family Affairs, Republic of Korea (A085138).
REFERENCES
1. Ab r am s P , Car d o zo  L, Fall M, Griffith s D, R o sier  P , Ulm ste n  
U, Van Kerrebroeck P, Victor A, Wein A. Standardisation 
Sub-Committee of the International Continence Society. The 
standardisation of terminology in lower urinary tract function: 
report from the standardisation sub-committee of the 
International Continence Society. Urology.  2003;61:37-49.
2. Wein A, Lose GR, Fonda D. Nocturia in men, women and the 
elderly: a practical approach. BJU Int. 2002;90 Suppl 3:28-31.
3. Homma Y, Yamaguchi T, Kondo Y, Horie S, Takahashi S, 
Kitamura T. Significance of nocturia in the International 
Prostate Symptom Score for benign prostatic hyperplasia. J 
Urol.  2002;167:172-176.
4. Appell RA, Sand PK. Nocturia: etiology, diagnosis, and treat-
ment.  Neurourol Urodyn. 2008;27:34-39.
5. Garfinkel D, Laudon M, Nof D, Zisapel N. Improvement of sleep 
quality in elderly people by controlled-release melatonin. Lan-
cet. 1995;346:541-544.
6. Haim o v  I, Lav ie  P , Lau d o n  M, He r e r  P , Vig d e r  C, Zisap e l N. 
Melatonin replacement therapy of elderly insomniacs. Sleep. 
1995;18:598-603.
7. Drake MJ, Mills IW, Noble JG. Melatonin pharmacotherapy for 
nocturia in men with benign prostatic enlargement. J Urol. 
2004;171:1199-1202.
8. Sugaya K, Nishijima S, Miyazato M, Kadekawa K, Ogawa Y. 
Effects of melatonin and rilmazafone on nocturia in the elderly. 
J Int Med Res. 2007;35:685-691.
9. Matsu ta Y, Yusu p  A, Tanase K, Ish id a H, Akin o  H, Yo k o y am a 
O. Melatonin increases bladder capacity via GABAergic system 
and decreases urine volume in rats. J Urol. 2010;184:386-391. 
10. Semerciöz A, Onur R, Ayar A, Orhan I. The inhibitory role of 
melatonin on isolated guinea-pig urinary bladder: an endogen-
ous hormone effect. BJU Int. 2004;94:1373-1376.
11. Pandi-Perumal SR, Trakht I, Srinivasan V, Spence DW, 
Maestroni GJ, Zisapel N, Cardinali DP. Physiological effects 
of melatonin: role of melatonin receptors and signal trans-
duction pathways. Prog Neurobiol. 2008;85:335-353. 
12. Ayar A, Kutlu S, Yilmaz B, Kelestimur H. Melatonin inhibits 
spontaneous and oxytocin-induced contractions of rat myome-
trium in vitro. Neuro Endocrinol Lett. 2001;22:199-207.
13. Thor PJ, Krolczyk G, Gil K, Zurowski D, Nowak L. Melatonin 
and serotonin effects on gastrointestinal motility. J Physiol 
Pharmacol.  2007;58 Suppl 6:97-103.
14. Abrams P, Andersson KE. Muscarinic receptor antagonists for 
overactive bladder. BJU Int. 2007;100:987-1006.
15. Drake MJ. Emerging drugs for treatment of overactive bladder 
and detrusor overactivity. Expert Opin Emerg Drugs. 2008;13: 
431-446.
16. Nowak JZ, Zawilska JB. Melatonin and its physiological and 
therapeutic properties. Pharm World Sci. 1998;20:18-27.
17. Onur R, Ozcan M, Tuygun U, Ozan T, Ayar A, Orhan I. Effects 
of combined use of trospium chloride and melatonin on in vitro 
contractility of rat urinary bladder. Urology. 2010;75:873-877.
18. Pressman MR, Figueroa WG, Kendrick-Mohamed J, Greenspon 42 JH Han, et al
LW, Peterson DD. Nocturia. A rarely recognized symptom of 
sleep apnea and other occult sleep disorders. Arch Intern Med. 
1996;156:545-550.
19. Salvatore S, Soligo M, Proietti F, Citterio S, Artibani W, Milani 
R. Overactive bladder syndrome: considerations in pharmaco-
therapy and new perspectives. Eur J Obstet Gynecol Reprod 
Biol. 2005;120:129-133. 
20. Cogé F, Guenin SP, Fery I, Migaud M, Devavry S, Slugocki 
C, Legros C, Ouvry C, Cohen W, Renault N, Nosjean O, 
Malpaux B, Delagrange P, Boutin JA. The end of a myth: 
cloning and characterization of the ovine melatonin MT(2) 
receptor.  Br J Pharmacol. 2009;158:1248-1262. 
21. Ouyang H, Vogel HJ. Melatonin and serotonin interactions 
with calmodulin: NMR, spectroscopic and biochemical studies. 
Biochim Biophys Acta. 1998;1383:37-47.
22. Ozveren E, Korkmaz B, Buharalioglu CK, Tunctan B. 
Involvement of calcium/calmodulin-dependent protein kinase II 
to endotoxin-induced vascular hyporeactivity in rat superior 
mesenteric artery. Pharmacol Res. 2006;54:208-218.